SHINE Technologies Acquires Lantheus' SPECT Business

Lantheus Acquires Life Molecular Imaging from Life Healthcare

July 22, 2025

Healthcare Services

Lantheus Holdings, Inc. completed the acquisition of Life Molecular Imaging Ltd., a subsidiary of Life Healthcare Group Holdings Ltd., gaining the Neuraceq (florbetaben F18) commercial product, expanded Alzheimer’s radiodiagnostic infrastructure, and additional R&D capabilities. As part of the transaction, Dr. Ludger Dinkelborg (formerly CEO of Life Molecular) will join Lantheus as Head of Research & Development, reporting to the CEO.

Lantheus Holdings Acquires Cerveau Technologies

February 6, 2023

Pharmaceuticals

Lantheus Holdings, Inc. acquired Knoxville-based Cerveau Technologies, Inc., gaining MK-6240, a clinical-stage F-18 PET imaging agent that targets Tau tangles in Alzheimer's disease. The stock purchase includes upfront and potential milestone payments plus royalty obligations and will expand Lantheus' radiopharmaceutical diagnostic imaging pipeline and research collaborations.

Bruker Corporation Acquires Spectral Instruments Imaging

February 6, 2024

Medical Devices

Bruker Corporation has acquired Spectral Instruments Imaging LLC, a Tucson-based maker of preclinical in‑vivo optical imaging systems, to broaden Bruker BioSpin's preclinical imaging portfolio. Financial terms were not disclosed; SII generated over $10 million in revenue in 2023 and will expand Bruker's capabilities in bioluminescence, fluorescence and X‑ray preclinical imaging.

Full-Life Technologies Acquires Focus‑X Therapeutics

November 28, 2022

Biotechnology

Full‑Life Technologies, a global radiotherapeutics company, agreed to acquire New Jersey‑based Focus‑X Therapeutics to expand its peptide‑focused radiopharmaceutical pipeline. Focus‑X shareholders are eligible for an upfront payment plus up to $245 million in development, regulatory and sales milestones and royalties; the deal was expected to close in Q1 2023.

LIXTE Biotechnology Acquires Liora Technologies Europe Ltd

November 25, 2025

Medical Devices

LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT) has completed the acquisition of Liora Technologies Europe Ltd., a UK-based developer of the LiGHT proton therapy system. The deal brings Liora's proprietary LiGHT System and Daresbury-based operations into LIXTE as a wholly owned subsidiary to expand the company's capabilities into radiotherapy and pursue joint treatment-center revenue models.

Lantheus Acquires Meilleur Technologies (NAV-4694)

July 15, 2024

Pharmaceuticals

Lantheus Holdings, Inc. announced the acquisition of Meilleur Technologies, Inc., giving Lantheus worldwide exclusive rights to NAV-4694 (F18-flutafuranol), a Phase 3 ß-amyloid PET imaging agent for Alzheimer’s disease. The deal includes an upfront payment plus potential development/commercial milestones and royalties, and the sellers will provide transition and clinical development services following closing.